Pandemic Influenza A H1N1 2009 Infection versus Vaccination: A Cohort Study Comparing Immune Responses in Pregnancy by Fisher, Barbra M. et al.
Pandemic Influenza A H1N1 2009 Infection versus
Vaccination: A Cohort Study Comparing Immune
Responses in Pregnancy
Barbra M. Fisher
1, Janice Van Bockern
1, Jan Hart
1, Anne M. Lynch
1, Virginia D. Winn
1, Ronald S. Gibbs
1,3,
Adriana Weinberg
2*
1Department of Obstetrics and Gynecology, Section of Maternal-Fetal Medicine, University of Colorado School of Medicine, Aurora, Colorado, United States of America,
2Departments of Pediatrics, Medicine, and Pathology, University of Colorado School of Medicine, Aurora, Colorado, United States of America, 3Novartis Diagnostics and
Therapeutics, Emeryville, California, United States of America
Abstract
Background: With the emergence of H1N1 pandemic (pH1N1) influenza, the CDC recommended that pregnant women be
one of five initial target groups to receive the 2009 monovalent H1N1 vaccine, regardless of prior infection with this
influenza strain. We sought to compare the immune response of pregnant women to H1N1 infection versus vaccination and
to determine the extent of passive immunity conferred to the newborn.
Methods/Findings: During the 2009-2010 influenza season, we enrolled a cohort of women who either had confirmed
pH1N1 infection during pregnancy, did not have pH1N1 during pregnancy but were vaccinated against pH1N1, or did not
have illness or vaccination. Maternal and umbilical cord venous blood samples were collected at delivery. Hemagglutination
inhibition assays (HAI) for pH1N1 were performed. Data were analyzed using linear regression analyses. HAIs were
performed for matched maternal/cord blood pairs for 16 women with confirmed pH1N1 infection, 14 women vaccinated
against pH1N1, and 10 women without infection or vaccination. We found that pH1N1 vaccination and wild-type infection
during pregnancy did not differ with respect to (1) HAI titers at delivery, (2) HAI antibody decay slopes over time, and (3) HAI
titers in the cord blood.
Conclusions: Vaccination against pH1N1 confers a similar HAI antibody response as compared to pH1N1 infection during
pregnancy, both in quantity and quality. Illness or vaccination during pregnancy confers passive immunity to the newborn.
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Introduction
Among healthy individuals infected with the influenza virus,
pregnant women and infants younger than 6 months of age are at
increased risk for serious complications when compared to other
groups [1-3]. These complications include preterm labor, preterm
delivery, and pregnancy loss among pregnant women and
pneumonia, dehydration, sinus problems and ear infections in
infants [4]. Vaccination is the best method to avoid influenza
infection and subsequent complications, and even death, among
affected pregnant women and their neonates. In 2009, influenza
vaccination was recommended for all women pregnant or
planning to become pregnant during influenza season [5,6]. In
addition to protecting the pregnant woman, vaccination also
protects the newborn from influenza-related complications. This
mode of neonatal acquisition of antibodies is extremely important,
since influenza vaccines have poor immunogenicity during the first
six months of life [7,8]. Following maternal vaccination, antibodies
are actively transferred from the maternal circulation to the fetus
via the placenta, providing passive immunity to the neonate
[9,10].
Pandemic influenza A H1N1 (pH1N1) emerged as a threatening
pathogen in April 2009. Its effects were realized both nationally
and worldwide, and resulted in remarkable morbidity and
mortality for both pregnant women and infants [11-13]. During
the 2009-2010 influenza season, a monovalent vaccine against
influenza A pH1N1 virus was developed and recommended as an
adjunct to seasonal influenza vaccination among high-risk groups,
which included pregnant women [14]. Consistent with seasonal
influenza vaccination recommendations, administration of this
vaccine was not intended for children younger than 6 months of
age. It was expected that the influenza A pH1N1 vaccination,
administered to pregnant women, would confer protection to their
neonates similarly to seasonal influenza vaccination [10,15].
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have focused on the antibody response to vaccination. We found
no reports of the immune response to wild-type influenza infection
during pregnancy in the literature. Here, we characterize the
antibody response during pregnancy to influenza A pH1N1
vaccination as well as wild-type infection and demonstrate that
passive immunity to the neonate results from provocation of
maternal antibody production from either vaccination or infection.
Materials and Methods
Patient recruitment
This prospective cohort study was approved by the IRB at the
University of Colorado School of Medicine (study 09-0970). All
patients gave written consent at time of enrollment in this study
and the clinical investigation was conducted according to the
principles expressed in the Declaration of Helsinski.
Pregnant women were recruited for this study upon admission to
labor and delivery from November 2, 2010 through June 17, 2011.
During the 2009-2010 influenza season, the University of Colorado
Hospital (UCH) instituted a triage system (influenza triage system)
whereby all high-risk individuals with influenza-like illness (ILI),
includingpregnantwomen,wouldbeevaluatedinpersonand tested
for influenza infection. Based on local and worldwide reports, all
circulatinginfluenzaAduringthisinfluenzaseasonwaspresumedto
be the pandemic H1N1 influenza A strain. Respiratory specimens
were obtained from patients and rapid antigen influenza A testing
was performed. Based on the low sensitivity of the rapid test, 19% in
one study [16], all specimens with negative results had reflex PCR
testing performed. All patients with a positive result from either the
rapid antigen test or PCR test were presumed to have been infected
with the influenza A pH1N1 virus.
The influenza triage system at UCH and subsequent electronic
record-keeping of all triaged patients and their accompanying test
results allowed us to identify women infected with pH1N1
influenza during pregnancy. For this study, three different groups
of pregnant women were identified and recruited (Infected,
Vaccinated, and Control). The Infected group was comprised of women
infected with laboratory-confirmed pH1N1 influenza during the
current pregnancy, with or without vaccination. The Vaccinated
group was comprised of women vaccinated against the pH1N1
influenza virus during the current pregnancy based upon review of
the medical records and without ILI during pregnancy. The Control
group was comprised of women reporting neither ILI nor pH1N1
influenza vaccination during pregnancy or preconception during
the 2009-2010 influenza season. Individuals in the Vaccinated and
Control groups were matched to individuals in the Infected group
based on gestational age at delivery, parity, and planned mode of
delivery. Women with antepartum pH1N1 infection, vaccination,
or neither were identified at time of admission to labor and
delivery and consented for study enrollment at that time.
Specimen collection, processing, and assays performed
At the time of study enrollment, maternal sera were collected,
aliquoted, and stored at 280uC. At delivery, umbilical cord
venous blood was collected similarly, aliquoted, and stored at
280uC. In batches, hemagglutination inhibition (HAI) assays were
performed for paired maternal/umbilical cord venous sera
samples, as described previously [17]. Serum dilution started at
1:10. Sera with HAI titers , 1:10 were arbitrarily ascribed a value
of 1:5 for calculations of geometric mean titers. The technician
performing the HAI assays was blinded to the specimen’s group
assignment and whether the specimen originated from maternal or
umbilical cord blood.
Ascertainment of pregnancy characteristics
We used records from the Perinatal Database of the
Department of Obstetrics and Gynecology at the University of
Colorado School of Medicine to obtain information regarding
maternal racial/ethnic group (non-Hispanic white, Hispanic,
black, Asian, and other) and pregnancy characteristics (parity
and gestational age (based on last menstrual period and
ultrasound)). Information on these and other perinatal variables
is collected by research assistants on every woman delivering at
UCH. This information is entered into a database housed in the
Division of Biostatistics and Bioinformatics at National Jewish
Health, Denver, CO. During the 2009-2010 influenza season, an
H1N1 Questionnaire, an adjunct to the Perinatal Database, was
developed and administered to postpartum women delivering at
UCH [18]. Clinical information related to ILI dates and
symptoms, pH1N1 influenza testing, and pH1N1 influenza
vaccination were obtained by administering the H1N1 Question-
naire to all patients enrolled in the current study.
Statistical analysis
The data were analyzed in SAS 9.2 (SAS Institute, Cary, NC).
Linear regression models were used to investigate the antibody
response during pregnancy to influenza A pH1N1 vaccination and
wild-type infection and investigate passive immunity to the
neonate. Comparisons among groups were considered significant
if p , 0.05. When expressing reciprocal antibody titers, the
logarithm of the antibody titer was used to best fit linear equations;
for Figures 1 and 2, the reciprocal antibody titer is shown on the
relevant axes.
Results
Characteristics of the study population
We enrolled 40 women in this study: 16 women with confirmed
pH1N1 infection during pregnancy (Infected), 14 women with
documented pH1N1 vaccination during the pregnancy (Vaccinated),
and 10 control women (Control) who were neither infected nor
vaccinated. Of the 16 women in the Infected group, four were also
vaccinated against pH1N1 influenza. One woman was vaccinated
three days prior to presenting with influenza-like illness, and the
other three patients were vaccinated between five and seven weeks
following confirmed pH1N1 influenza infection. All analyses were
performed with both inclusion and exclusion of these four patients
in the Infected group; since there were no statistical differences
between results with either inclusion or exclusion of these four
patients, we opted to keep them included in the Infected group. We
compared the characteristics of the Infected women, the Vaccinated
women, and the Control women (Table 1). At study enrollment,
matching based on gestational age at delivery, parity, and planned
mode of delivery was performed. As shown in Table 1, the groups
were indeed similar with respect to these characteristics. In
addition, the groups did not differ with respect to maternal age,
gestational age at time of pH1N1 infection or vaccination, or race/
ethnicity. The only difference among groups was BMI, with the
mean BMI in the control group being higher.
HAI antibody titers in women with pH1N1 wild-type
infection or vaccination during pregnancy
In Figure 1, we show the geometric mean titers (GMT) for the
Infected, Vaccinated, and Control groups of women. The GMT
following pH1N1 infection or vaccination is similar, with the
Infected and Vaccinated groups differing from the GMT for the
Control healthy, non-vaccinated, patients. Four subjects in the
Infected group received the vaccine during pregnancy (three of
Pandemic Influenza A in Pregnancy
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documented wild-type infection as per the recommendations for
universal influenza vaccination during pregnancy [6]. The GMT
at delivery for these four subjects was 1:160, which did not differ
statistically from the GMT at delivery for the non-vaccinated
Infected patients (1:71; p=0.32).
HAI antibody titers $ 1:40 are considered to be relevant
clinically, and are considered to result in a 50% decrease in
symptomatic infection [19]. Whether a woman had confirmed
pH1N1 infection or vaccination, the mean titer was at, or greater
than, this threshold value, suggesting sufficient immunity toward
the pH1N1 influenza virus. Control patients, individuals who had
neither pH1N1 infection nor vaccination, had HAI titers well
below this threshold value, suggesting no immunity toward
pH1N1 influenza.
Influenza-specific antibodies after vaccination are typically
short-lived. To determine if antibody decay differed between
wild-type infection or vaccination during pregnancy, we evaluated
the relationship between the maternal HAI titers and days elapsed
between pH1N1 infection or vaccination and blood draw at time
of admission to labor and delivery (Figure 2). There is a linear
correlation between these titers and days elapsed between pH1N1
infection or vaccination for both groups. In this figure, we
demonstrate that there was a significant linear decline over time in
HAI titers after pH1N1 infection or vaccination (p=0.04 for
Infected and p=0.009 for Vaccinated). Furthermore, the rate of decay
of pH1N1 antibodies, measured by the slope of the HAI titers over
time, was similar for antibodies produced in response to wild-type
infection or vaccination (20.010 and 20.013, respectively;
p=0.60). A sensitivity analysis performed by censoring the data
of the four women who were both vaccinated and had wild-type
infection showed similar results.
Transplacental transfer of pH1N1 antibodies after wild-
type infection or vaccination during pregnancy
In Figure 3, we show the relationship between maternal and
cord blood HAI titers. There was a linear relationship between
maternal and cord HAI titers after wild-type infection or
vaccination (R
2=0.76 for Infection and R
2=0.92 for Vaccinated),
demonstrating efficient transplacental transfer of pH1N1 influenza
Figure 1. Geometric mean titers for the cohort.
doi:10.1371/journal.pone.0033048.g001
Figure 2. Persistence of maternal antibodies to pandemic H1N1 influenza following wild-type infection or vaccination.
doi:10.1371/journal.pone.0033048.g002
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was similar for both groups (p=0.85).
Discussion
In this cohort, we demonstrate that pregnant women exposed to
either wild-type pH1N1 infection or pH1N1 vaccination produce
antibodies sufficient to provide short-term protection against
homotypic influenza infection. An HAI antibody titer of 1:40 after
vaccination is the current standard for licensure of influenza
vaccines and a widely accepted surrogate for protection against
influenza infection [19]. In this study, women who were infected
with or vaccinated against pH1N1 had GMTs during pregnancy
above this threshold value, suggesting protection against this
specific influenza strain.
It has been shown that antibodies against one influenza virus
type or subtype confer limited or no protection against other types
or subtypes of influenza virus [20]. In a typical influenza season,
when there may be three or four influenza strains circulating in the
community, documented influenza infection does not preclude the
need for vaccination, which may confer protection against
additional strains. However, in a season such as 2009-2010 when
a monovalent preparation is used to protect against a single
influenza strain, confirmed infection should negate the need for
strain-specific vaccination, as shown by the similar antibody
response to either infection or vaccination. Four of our patients
with confirmed pH1N1 infection were also vaccinated, according
to the recommendations of the CDC. These four patients had a
non-significant increased (2-fold) antibody titer when compared to
either the Infected or Vaccinated patients. After analyzing our data
with both the inclusion and exclusion of these four patients, we
found that their inclusion in the Infected group did not change the
results reported herein.
Although pH1N1 infection and vaccination resulted in similar
HAI antibody titers, these results do not completely establish that
the level of protection afforded to an individual, following either
infection or vaccination, are the same. For example, elderly
individuals are less likely to develop influenza illness if they had
infection rather than vaccination in the preceding season [21].
Similarly, the incidence of infection with pH1N1 in 2009-2010
Table 1. Characteristics of the cohort (n=40).
Infected (n=16) Vaccinated (n=14) Control (n=10) p value
Maternal Age (years), mean6SD 26.163.7 27.465.6 25.664.6 0.62
Race/Ethnicity, n (%)
Hispanic 3 (18.7) 5 (35.7) 4 (40.0) 0.17
White 9 (56.3) 9 (64.3) 3 (30.0)
Other/mixed 4 (25) 0 (0.0) 3 (30.0)
BMI, mean6SD 26.064.6 24.965.6 31.9610.1 0.04
Gestational age at delivery (wks), mean6SD 39.162.1 39.461.0 39.861.4 0.57
Gestational age at H1N1 infection or vaccination
(wks), mean6SD
21.7610.5 17.7613.1 n/a 0.37
doi:10.1371/journal.pone.0033048.t001
Figure 3. Transplacental transfer of antibodies to pandemic H1N1 influenza following wild-type infection or vaccination.
doi:10.1371/journal.pone.0033048.g003
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vaccinationcomparedwithunvaccinatedindividualsofthesameage
[22]. The inactivated vaccine generates much lower cell-mediated
immune responses compared with wild-type infection. The
influenza-specific cell-mediated immunity, and particularly gran-
zymeB-producing cytotoxic T-lymphocytes,appeartobe critical for
protection against disease [23]. It also confers heterosubtypic cross-
protection, since there is higher similarity among T-cell compared
with B-cell epitopes among different influenza serotypes [24,25].
Live attenuated vaccines tend to generate higher levels of cell-
mediated immune responses that do inactivated preparations.
However, they are contraindicated in pregnancy. The use of
adjuvants may also increase cell-mediated immune responses to
inactivated vaccines and deserve to be studied further.
We show that antibody titers decline over time, and this decline
is similar whether antibodies are produced in response to wild-type
pH1N1 infection or pH1N1 vaccination. This decline could have
clinical significance for an influenza season with atypical timing,
such as the 2009-2010 pH1N1 influenza outbreak. In contrast to
typical influenza seasons where the population is immunized in the
fall months with peak influenza season activity seen during the
subsequent winter months, the H1N1 pandemic began during
springtime, peaked during the summer, persisted through the
following winter, and reappeared in the subsequent influenza
season. Here, at approximately 150 days for the vaccinated
women and 225 days for the infected women, the line of best fit for
the antibody titer in response to vaccine or infection crossed below
the 1:40 antibody titer threshold. For select women in this cohort
who received vaccination early in pregnancy, greater than 150
days elapsed between vaccination and delivery. This observation
lends the question: should repeat vaccination for an atypically-
timed influenza strain be encouraged for pregnant women
vaccinated early in pregnancy? Further, these data support
national recommendations for yearly influenza vaccination.
Vaccine administration to pregnant women has been used to
protect infants against infection in the first few months of life. The
best example of success in this strategy is the dramatic decline in
the incidence of neonatal tetanus in response to maternal
immunization [26,27]. A similar strategy could be used to prevent
influenza in young infants who are at high risk of developing
severe disease if infected with influenza, but in whom current
vaccines have poor immunogenicity. Indeed, Zaman et al.
demonstrated that inactivated influenza vaccine administered to
pregnant women resulted in a 63% reduction in laboratory-proven
infection in infants up to 6 months of age and reductions of 29%
and 36% in rates of respiratory illness with fevers in infants and
mothers [9]. Subsequent independent studies confirmed these
results [10]. The decreased incidence of influenza in infants after
maternal immunization could result from passive immunity
acquired through transplacental transfer of maternal antibodies
and/or from decreased exposure to maternal influenza infection.
Here, we examined transplacental antibody transfer following
pH1N1 vaccination. Administration of the 2009 monovalent
pH1N1 vaccination to pregnant women resulted in detectable
antibodies in umbilical cord venous blood with GMTs $ 1:40.
This finding is consistent with previous studies with seasonal
influenza vaccination [28]. Notably, following pH1N1 wild-type
infection, a similar linear relationship between maternal and
umbilical cord antibody titers was observed.
The main limitation of this study was the small number of
participants. Despite gathering a research team rapidly and
obtaining IRB approval for this study in a timely fashion, we
were limited by the relatively small number of women at our
institution with confirmed pH1N1 infection or vaccination during
pregnancy and to the difficulty of enrolling patients who were
identified as potential study candidates during labor. Another
limitation of this study is that baseline antibody titers, prior to
vaccination administration, were not available in the vaccination
group. It is possible that some of the women in this group had
previous asymptomatic infection, and that prior infection might
have bolstered the immune response, affecting the comparison
between the vaccinated and infected groups of women. Each
woman in this study, prior to enrollment, was interviewed to insure
no pH1N1 infection during pregnancy. Among the 813 women
that we screened for study enrollment, 122 reported symptoms
consistent with influenza-like illness and were tested for H1N1
infection. Of these women, only 38 (38/813=5%) had confirmed
pH1N1 infection (Fisher et al., data presented at the 2009 IDSOG
annual meeting). Assuming that 25-30% of the pH1N1 infections
were asymptomatic [29,30], a conservative estimate would be that
up to 2% of the participants in the vaccination group may have
had asymptomatic infection in addition to vaccination. Hence it is
unlikely that asymptomatic infection biased our results.
In summary, this study demonstrates that vaccination against
pH1N1 confers a similar antibody response as compared to pH1N1
infection during pregnancy, in quantity, quality, and persistence. In
addition, both illness and vaccination during pregnancy confers
passive immunity to the newborn. These findings support repeat
vaccination of pregnant women during each influenza season,
regardless of infection or vaccination in the previous season, but do
not support administration of monovalent influenza vaccines to
pregnant women who already experienced infection with the same
vaccine strain in the same season. In future influenza pandemics
where a monovalent vaccination is available, guidelines for
vaccination of individuals with prior confirmed infection should
be re-evaluated. In addition, for atypically-timed influenza
outbreaks (such as that seen during the 2009-2010 H1N1 influenza
pandemic), where a woman might be vaccinated during the first
trimester and influenza is still circulating months later at time of
delivery, a booster dose might be considered for the benefit of the
neonate. This recommendation warrants further investigation.
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